NOS3 and benign prostatic hyperplasia: NOS3 transcript relative levels (NOS3:B2M > 0.8) were 4-fold higher in PCa than in BPH, and due to its bimodal behavior, the NOS3 levels may be used as a biomarker together with the PCA3 marker for molecular staging of the disease.